FTS Study in Patients With Advanced Hematologic Malignancies

Phase 1 Completed 18 enrolled M.D. Anderson Cancer Center Concordia Pharmaceuticals, Inc · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Primary Objective: Determining the maximum tolerated dose (MTD) and pharmacokinetics (PK) of FTS (S-Trans, Trans-Farnesylthiosalicylic Acid) after daily oral administration on Days 1 through 21 of a 28-Day cycle to patients with advanced hematologic malignancies that have progressed following effective therapy or for which no effective therapy exists.

Timeline

Start: 2006-05
Primary completion: 2009-02
Completion: 2009-02

Publications

Laheru D, Shah P, Rajeshkumar NV, McAllister F, Taylor G, Goldsweig H, Le DT, Donehower R, Jimeno A, Linden S, Zhao M, Song D, Rudek MA, Hidalgo M. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs. 2012 Dec;30(6):2391-9. doi: 10.1007/s10637-012-9818-6. Epub 2012 May 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	S-trans,trans-Farnesylthiosalicylic Acid	Unknown	100 mg	Oral

FTS Study in Patients With Advanced Hematologic Malignancies

Summary

Timeline

Publications

Drugs

Indications